Dr. Shaker Dakhil, M.D.
Claim this profileCancer Center of Kansas - Wichita
Expert in Cancer
Expert in Lung Cancer
83 reported clinical trials
170 drugs studied
About Shaker Dakhil, M.D.
Education:
- Earned an MD from St. Joseph University School of Medicine, Beirut, Lebanon, in 1975.
Experience:
- Completed Residency in Internal Medicine at Wayne State University, Detroit, Michigan.
- Undertook a Fellowship in Hematology/Oncology at the University of Michigan.
- Certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine.
- President of the Cancer Center of Kansas since 2000 and a Clinical Professor of Medicine at the University of Kansas School of Medicine – Wichita.
- Founder of the Wichita Cancer Foundation and recipient of multiple awards for excellence in oncology.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Shaker Dakhil, M.D. is currently running
Talazoparib + Temozolomide
for Small Cell Lung Cancer
This trial studies how effective talazoparib and temozolomide are for treating patients with extensive-stage small cell lung cancer that has come back after initial chemotherapy. Talazoparib stops cancer cells from repairing their DNA, while temozolomide kills or stops the growth of these cells. The combination may work better than either drug alone.
Recruiting1 award Phase 219 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
More about Shaker Dakhil, M.D.
Clinical Trial Related5 years of experience running clinical trials · Led 83 trials as a Principal Investigator · 36 Active Clinical TrialsTreatments Shaker Dakhil, M.D. has experience with
- Carboplatin
- Cisplatin
- Nivolumab
- Atezolizumab
- Paclitaxel
- Pembrolizumab
Breakdown of trials Shaker Dakhil, M.D. has run
Cancer
Lung Cancer
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shaker Dakhil, M.D. specialize in?
Shaker Dakhil, M.D. focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Shaker Dakhil, M.D. currently recruiting for clinical trials?
Yes, Shaker Dakhil, M.D. is currently recruiting for 35 clinical trials in Wichita Kansas. If you're interested in participating, you should apply.
Are there any treatments that Shaker Dakhil, M.D. has studied deeply?
Yes, Shaker Dakhil, M.D. has studied treatments such as Carboplatin, Cisplatin, Nivolumab.
What is the best way to schedule an appointment with Shaker Dakhil, M.D.?
Apply for one of the trials that Shaker Dakhil, M.D. is conducting.
What is the office address of Shaker Dakhil, M.D.?
The office of Shaker Dakhil, M.D. is located at: Cancer Center of Kansas - Wichita, Wichita, Kansas 67214 United States. This is the address for their practice at the Cancer Center of Kansas - Wichita.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.